

NCT03376763 comparison:

Summary:
CHIA has 17 criteria while your personal folder has 17 criteria
Total found criteria: 7/17
Total not Found: 10/17
Total Extra: 19
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Subject who showed medically significant adverse   │ Subject who showed medically significant adverse   │
│ events or intolerance with aripiprazole during     │ events or intolerance with aripiprazole during     │
│ screening period or as prior experiences           │ screening period or as prior experiences           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with diseases of the central nervous      │ Subjects with diseases of the central nervous      │
│ system that may impact the assessment of the       │ system that may impact the assessment of the       │
│ psychotic symptoms as per investigator's opinion   │ psychotic symptoms as per investigator's opinion   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with a significant risk of violent        │ Subjects with a significant risk of violent        │
│ behaviour or a significant risk of committing      │ behavior or a significant risk of committing       │
│ suicide based on history or investigator's         │ suicide based on history or investigator's         │
│ judgment                                           │ judgment                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects had a history of seizures, neuroleptic    │ Subjects had a history of seizures, neuroleptic    │
│ malignant syndrome, clinically significant tardive │ malignant syndrome, clinically significant tardive │
│ dyskinesia, or other medical condition that would  │ dyskinesia, or other medical condition that would  │
│ expose them to undue risk or interfere with study  │ expose them to undue risk or interfere with study  │
│ assessments                                        │ assessments                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant history of drug abuse disorder         │ Significant history of drug abuse disorder         │
│ (including alcohol, as defined in DSM-5 substance  │ (excluding caffeine and nicotine, including        │
│ use disorder or in the opinion of the              │ alcohol, as defined in DSM-5 substance use         │
│ investigator) within the last 6 months prior to    │ disorder or in the opinion of the investigator)    │
│ screening                                          │ within the last 6 months prior to screening        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects participating another interventional      │ Subjects who participated in another               │
│ clinical trial within 30 days prior to screening   │ interventional clinical trial within 30 days prior │
│                                                    │ to screening                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects having any other clinically significant   │ Subjects having any other clinically significant   │
│ finding of the physical examination or laboratory  │ finding of the physical examination or laboratory  │
│ value that make investigator consider that it      │ value that make investigator consider that it      │
│ would be inappropriate to participate in this      │ would be inappropriate to participate in this      │
│ study                                              │ study                                              │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Subjects must be capable of providing signed and dated written informed consent by date of Visit 0   │
│ (-2 week)                                                                                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Male and female aged =19 and < 65 years                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects diagnosed of schizophrenia as defined by Diagnostic and Statistical Manual of Mental        │
│ Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria, and a history   │
│ of illness for at least for 3 years prior to screening                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who take atypical antipsychotic drugs, and should be maintained on current antipsychotic    │
│ drugs (including atypical antipsychotic drugs) and dose for at least 4 weeks prior to the screening  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching │
│ to long-acting injectable aripiprazole in the investigator's judgement                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to    │
│ comply with all protocol procedures                                                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects with a current DSM-<U+2163>-TR or 5 diagnosis other than schizophrenia, including           │
│ schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnesia,  │
│ Borderline, Paranoid, Histrionic, Schizotypal, Schizoid, Antisocial or other cognitive or            │
│ personality disorders                                                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who have been treated with clozapine or long-acting injectable antipsychotic drugs within 3 │
│ months prior to the screening                                                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who have been treated over maximum maintenance dose (as specified in each label) of oral    │
│ antipsychotics at screening. (e.g. Aripiprazole>30mg/day, Olanzapine>20mg/day, Risperidone >         │
│ 6mg/day, Quetiapine > 750mg/day)                                                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women who are pregnant, nursing, or who plan to become pregnant while in the trial                   │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Subjects who take atypical antipsychotic drugs with the therapeutic effective dose (as specified in  │
│ each label) for schizophrenia treatment, and should be maintained on the type and dose of the        │
│ current antipsychotic drugs (including both typical and atypical antipsychotic drugs) for at least 4 │
│ weeks prior to the screening                                                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects with a current DSM diagnostic criteria-based diagnosis other than schizophrenia, including  │
│ Schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, neurocognitive      │
│ disorder due to Alzheimer's or similar diseases, amnesia, borderline, paranoid, histrionic,          │
│ schizotypal, schizoid, antisocial or other cognitive or personality disorders                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Male and female legally aged ≥19 and \< 65 years                                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who have been treated more than 2 oral antipsychotic drugs (including both typical and      │
│ atypical antipsychotic drugs) with the minimum therapeutic effective dose (as specified in each      │
│ label) for schizophrenia treatment at screening                                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to    │
│ comply with all protocol procedures as per the investigator's judgment                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who have been treated with oral antipsychotic drugs (including both typical and atypical    │
│ antipsychotic drugs) exceeding maximum maintenance dose (as specified in each label) at screening    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Pregnant or lactating women, or women of childbearing potential who are not willing to or not able   │
│ to use contraceptive methods (sexual abstinence; oral, implanted or injection hormone contraceptive  │
│ methods; intrauterine device or condom; barrier contraceptive methods such as diaphragm and          │
│ spermicide), accepted to avoid pregnancy until the end of the clinical trial                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 64 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 19 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ (e.g. Aripiprazole≥10 mg/day, Olanzapine≥10 mg/day, Risperidone≥2 mg/day, Quetiapine ≥150 mg/day)    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who have been treated with clozapine, electroconvulsive therapy (ECT) or other long-acting  │
│ injectable antipsychotic drugs within 3 months prior to the screening                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ A. Outpatient subjects, with no hospitalization for worsening of schizophrenia within 3 months prior │
│ to screening                                                                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who were diagnosed of schizophrenia as defined by DSM diagnostic criteria, and were         │
│ diagnosed of schizophrenia for at least for 2 years prior to screening                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects with all of the following schizophrenia clinical features                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ B. Subjects who have no more than a moderate rating on the PANSS total score≤80 C. 4 individual      │
│ PANSS items, which are concerning to psychotic symptom (P2. conceptual disorganization, P3.          │
│ hallucinatory behavior, P6. suspiciousness/persecution, G9. unusual thought content), score≤4        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who voluntarily consented to participating in the clinical trial                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ (e.g. Aripiprazole\>30 mg/day, Olanzapine\>20 mg/day, Risperidone \> 6 mg/day, Quetiapine \> 750     │
│ mg/day)                                                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching │
│ to Abilify Maintena on the investigator's judgement                                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ D. CGI-S score ≤4 (moderately ill)                                                                   │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛